Project Grant R43AI197698
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $321K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03766, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Radar Therapeutics Inc. $306,928 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop in vivo CAR therapies for lupus treatment using selectively expressed genetic payloads in immune-cell-biased lipid nanoparticles. Radar Therapeutics is advancing its RADAR platform (ribonucleic acid sensing using adenosine deaminases acting on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $356,328 to Celdara Medical, LLC on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel allogeneic cell therapy for difficult-to-treat inflammatory bowel disease. Celdara will develop cell-based therapeutic candidates targeting the dysregulated immune response in IBD patients who fail multiple lines of conventional therapy or experience...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology $929,095 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize immune cell populations in lymphoid tissue from systemic lupus erythematosus patients and healthy controls using minimally invasive nasal swab sampling combined with flow cytometry and transcriptomic profiling. The research addresses gaps in understanding tissue-specific immune...
- The National Institute of Allergy and Infectious Diseases awarded $499,175 to the University of Pittsburgh on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genetic and functional dissection of tissue-infiltrating and age-associated B cells in murine lupus models. The research aims to identify and characterize pathogenic B cell subsets in systemic lupus erythematosus (SLE), with particular focus on age-associated B cells (ABCs) that...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $647,571 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory T cell dysfunction as a biomarker for personalized therapeutic targeting in systemic lupus erythematosus. The research uses single-cell transcriptomics to characterize two transcriptionally distinct patient subgroups based on naive regulatory T cell (nTreg)...
- The National Institute of Allergy and Infectious Diseases awarded Rarefied Biosciences, Inc. $626,352 on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test MALT1 inhibitors as a treatment for CARD11 gain-of-function, a rare pediatric inborn error of immunity. CARD11 gain-of-function is a rare genetic disorder caused by inborn variants in the CARD11 gene that produce a biochemical gain of function. In children, the condition causes...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $209,375 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of autophagy in B cell tolerance and its relationship to systemic lupus erythematosus. The research examines how autophagy defects contribute to loss of B cell tolerance in autoimmune disease, specifically exploring crosstalk between autophagy pathways and...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $306,810 to Capture Bioscience Inc. on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of a high-throughput autoimmune antibody detection platform. Capture Bioscience will adapt its Beads by Time-of-Flight (B-TOF) technology to create a comprehensive autoimmunity panel capable of simultaneously...
- The National Institute of Allergy and Infectious Diseases awarded Abterra Biosciences, Inc. $306,555 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a serum antibody repertoire analysis platform for diagnosing systemic lupus erythematosus. Abterra will develop CDR3-SEQ, a novel technology platform that profiles over 1,000 antibody sequences from serum by analyzing the complementarity determining region 3 (CDRH3), the key domain for...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Emory University $100,228 on November 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into autoreactive, extrafollicular B cell pathways in a TLR7-driven murine model. The project addresses gaps in understanding the origins of extrafollicular effector B cells and the system-wide and microenvironmental signaling that...